20 Results for "

gastro-intestinal barrier

" in MedChemExpress (MCE) Product Catalog:
Products (20)

20 Results for "gastro-intestinal barrier" in MCE Product Catalog:

32
32 Publications Verification
Cat. No.: HY-13771
CAS No.: 128-13-2
Purity:  99.94%
Synonyms: Ursodeoxycholate; Ursodiol; UDCA
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
loading...
    loading...
32
32 Publications Verification
Cat. No.: HY-13771A
CAS No.: 2898-95-5
Purity:  99.06%
Synonyms: Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B1164
CAS No.: 4093-35-0
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

Bromopride is a selective, irreversible, competitive, and orally effective dopamine D2 receptor antagonist. Bromopride can pass through the blood-brain barrier, inhibit the vomiting center, and enhance gastrointestinal motility, exerting antiemetic and gastrointestinal motility effects. Bromopride antagonizes dopamine-mediated vomiting reflexes and promotes gastrointestinal smooth muscle contraction, and has no adverse effects on abdominal wall healing in rats with postoperative abdominal infection. Bromopride can be used for the study of digestive system diseases (such as gastric hypomotility, nausea and vomiting) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-113478S
CAS No.: 347841-46-7
Purity:  99.52%
Synonyms: Ursodeoxycholate-d4; Ursodiol-d4; UDCA-d4
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-133813A
CAS No.: 72296-47-0
Purity:  ≥95.0%
Apovincaminic acid hydrochloride salt is the major metabolite of Vinpocetine (HY-13295), with blood-brain barrier permeability and oral activity. Apovincaminic acid hydrochloride salt is detectable in the plasma of pregnant rabbits after oral administration of Vinpocetine. Apovincaminic acid hydrochloride salt is absorbable from all segments of the gastrointestinal tract of Norway rat, with the stomach as the primary absorption site, and is excreted via urine and feces. Apovincaminic acid hydrochloride salt is used in the research of cerebrovascular diseases .
loading...
    loading...
Cat. No.: HY-107111
CAS No.: 932373-87-0
Purity:  98.78%
Target:  

mAChR

Research Areas:  

Neurological Disease

GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC50=8.1) that can cross the blood-brain barrier. GSK1034702 activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .
loading...
    loading...
Cat. No.: HY-164288
CAS No.: 2287331-29-5
Synonyms: TDI-006570
TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .
loading...
    loading...
Cat. No.: HY-13771R
CAS No.: 128-13-2
Synonyms: Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
loading...
    loading...
Cat. No.: HY-146391
CAS No.: 2652001-05-1
Target:  

P-glycoprotein

Research Areas:  

Cancer

P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC50 of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .
loading...
    loading...
Cat. No.: HY-13771S1
CAS No.: 63296-46-8
Synonyms: Ursodeoxycholate-13C; Ursodiol-13C; UDCA-13C
Ursodeoxycholic acid- 13C is the 13C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
loading...
    loading...
Cat. No.: HY-B1164A
CAS No.: 52423-56-0
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

Bromopride hydrochloride is a selective, irreversible, competitive, and orally active dopamine D2 receptor antagonist. Bromopride hydrochloride can pass through the blood-brain barrier, inhibit the vomiting center, and enhance gastrointestinal motility, exerting antiemetic and gastrointestinal motility effects. Bromopride hydrochloride antagonizes dopamine-mediated vomiting reflexes and promotes gastrointestinal smooth muscle contraction, and has no adverse effects on abdominal wall healing in rats with postoperative abdominal infection. Bromopride hydrochloride can be used for the study of digestive system diseases (such as gastric hypomotility, nausea and vomiting) .
loading...
    loading...
Cat. No.: HY-163415
CAS No.: 906728-07-2
Target:  

Monoamine Oxidase

Research Areas:  

Neurological Disease

MAO-IN-5 (Compound ZINC000016952895) is a monoamine oxidase (MAO) inhibitor. According to the prediction of Swiss ADME, MAO-IN-5 can inhibit the CYP enzyme family, has blood-brain barrier (BBB) permeability, and has a high gastrointestinal absorption rate. MAO-IN-5 can be used in the study of neurological diseases .
loading...
    loading...
Cat. No.: HY-133813AR
CAS No.: 72296-47-0
Apovincaminic acid hydrochloride salt (Standard) is the analytical standard of Apovincaminic acid hydrochloride salt (HY-133813A). This product is intended for research and analytical applications. Apovincaminic acid hydrochloride salt is the major metabolite of Vinpocetine (HY-13295), with blood-brain barrier permeability and oral activity. Apovincaminic acid hydrochloride salt is detectable in the plasma of pregnant rabbits after oral administration of Vinpocetine. Apovincaminic acid hydrochloride salt is absorbable from all segments of the gastrointestinal tract of Norway rat, with the stomach as the primary absorption site, and is excreted via urine and feces. Apovincaminic acid hydrochloride salt is used in the research of cerebrovascular diseases .
loading...
    loading...
Cat. No.: HY-133813S
Apovincaminic acid-d4 is the deuterated-labeled Apovincaminic acid (HY-133813). Apovincaminic acid is the major metabolite of Vinpocetine (HY-13295), with blood-brain barrier permeability and oral activity. Apovincaminic acid is detectable in the plasma of pregnant rabbits after oral administration of Vinpocetine. Apovincaminic acid is absorbable from all segments of the gastrointestinal tract of Norway rat, with the stomach as the primary absorption site, and is excreted via urine and feces. Apovincaminic acid is used in the research of cerebrovascular diseases .
loading...
    loading...
Cat. No.: HY-168241
CAS No.: 1639925-34-0
Research Areas:  

Infection

Flucopride (Compound 4a) is an AChE inhibitor (IC50: 24 nM), and a partial 5-HT4R agonist (Ki: 9.6 nM for (h)5-HT4R). Flucopride promotes the non-amyloidogenic processing of APP in COS-7 transiently expressing (h)5-HT4R (EC50: 23.0 nM). Flucopride may has good gastrointestinal track (GIT) penetration, and blood-brain barrier (BBB) cross-membrane penetration (PAMPA assay) .
loading...
    loading...
Cat. No.: HY-162373
Research Areas:  

Metabolic Disease

α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .
loading...
    loading...
Cat. No.: HY-107111A
CAS No.: 932373-86-9
Research Areas:  

Neurological Disease

GSK1034702 hydrochloride is an orally active and allosteric agonist of M1 mAChR (pEC50=8.1) that can cross the blood-brain barrier. GSK1034702 hydrochloride activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 hydrochloride can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 hydrochloride can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .
loading...
    loading...
Cat. No.: HY-133813
CAS No.: 27773-65-5
Apovincaminic acid is the major metabolite of Vinpocetine (HY-13295), with blood-brain barrier permeability and oral activity. Apovincaminic acid is detectable in the plasma of pregnant rabbits after oral administration of Vinpocetine. Apovincaminic acid is absorbable from all segments of the gastrointestinal tract of Norway rat, with the stomach as the primary absorption site, and is excreted via urine and feces. Apovincaminic acid is used in the research of cerebrovascular diseases .
loading...
    loading...
Cat. No.: HY-183540
CAS No.: 57558-44-8
Target:  

mAChR

Secoverine is a muscarinic cholinergic receptor (mAChR) antagonist and antispasmodic with blood-brain barrier permeability. Secoverine binds competitively to muscarinic receptors, blocks central cholinergic effects, and inhibits cholinergically induced gastrointestinal motility, intestinal smooth muscle contraction, and acetylcholine-mediated neurotransmitter release. Secoverine exerts direct antispasmodic activity on intestinal smooth muscle independent of receptor blockade, and exhibits characteristics such as reversible smooth muscle activity and long duration of action. Secoverine can be used in studies related to hyperintestinal motility, diverticular disease, and colonic spasm .
loading...
    loading...
Cat. No.: HY-107111R
CAS No.: 932373-87-0
Research Areas:  

Neurological Disease

GSK1034702 (Standard) is the analytical standard of GSK1034702 (HY-107111). This product is intended for research and analytical applications. GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC50=8.1) that can cross the blood-brain barrier. GSK1034702 activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .
loading...
    loading...
  • 1